TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7978718
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2 mg/d
Study: 8879340
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (cilazapril)
Study: 31393029
Drug: MI‐SI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI‐SI plus treatment as usual (TAU)
Study: 31393029
Drug: MI‐SI‐R plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI‐SI‐R plus treatment as usual (TAU)
Study: 25110374
Drug: Three rounds
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three rounds of azithromycin mass drug administration (MDA)
Study: 25110374
Drug: One round
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One round of azithromycin mass drug administration (MDA)
Study: 22468770
Drug: Values of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Values of Life‐Sustaining Treatment Outcomes
Study: 22468770
Drug: Dyad congruence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyad congruence in values for life‐sustaining treatment
Study: 17547539
Drug: DHA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA group (BSF plus fish oil DHA 200 mg)
Study: 7673021
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with bromodeoxyuridine (BrdUrd) 0.8 g/m2 per day for 4 days of each of 3 weeks
Study: 2041549
Drug: GM-1 ganglioside
Normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-1 ganglioside (100 mg intravenously per day for 18 to 32 doses)
Study: 2041549
Drug: Placebo (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenously per day for 18 to 32 doses)
Study: 31784343
Drug: PrEP (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP (300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine per pill)
Study: 30931709
Drug: 25% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% silver nitrate (AgNO3) solution followed by a 5% sodium fluoride (NaF) varnish, semiannually (every 6 months)
Study: 30931709
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride (SDF) solution followed by a placebo varnish, semiannually (every 6 months)
Study: 25976063
Drug: Carbetocin (100-µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100-µg i.v. bolus)
Study: 25976063
Drug: Intra-umbilical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-umbilical oxytocin (50 IU in 30 mL saline)
Study: 15942511
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (2 mg)
Study: 15942511
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (0.15 mg/kg)
Study: 9787368
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily
Study: 9787368
Drug: 2.0% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% dorzolamide administered three times daily
Study: 9787368
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol administered twice daily
Study: 27600055
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 843 mg of (−)-epigallocatechin-3-gallate (EGCG)
Study: 25869561
Drug: Fasudil (Rho
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (Rho kinase inhibitor)
Study: 15266215
Drug: Valdecoxib (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (10-80 mg daily)
Study: 15266215
Drug: Nonselective NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonselective NSAIDs (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid)
Study: 15266215
Drug: Users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Users of aspirin
Study: 15266215
Drug: Valdecoxib (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (therapeutic doses 10 or 20 mg daily and supratherapeutic doses 40 or 80 mg daily)
Study: 8833557
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention including diabetes education, medication counseling, dietary regulation, exercise, home blood glucose monitoring, and hypoglycemic regimen adjustment.
Study: 3886357
Drug: Felodipine 5mg
Normalized name: FELODIPINE 5MG TAB,SA
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 5mg three times daily
Study: 3886357
Drug: Nifedipine 10mg
Normalized name: NIFEDIPINE 10MG CAP
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 10mg three times daily
Study: 31702056
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg in 2 mL)
Study: 31702056
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg in 2 mL)
Study: 27884765
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg, Naproxen 200 mg, Oseltamivir 75 mg twice daily for 2 days, followed by Oseltamivir 75 mg twice daily for 3 days
Study: 27884765
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg twice daily for 5 days (control)
Study: 21367948
Drug: Carbohydrate-restricted diet
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-restricted diet (<20 g/d)
Study: 19761358
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro protamine suspension (ILPS) 0.8 U/kg
Study: 19761358
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (G) 0.8 U/kg
Study: 19761358
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (D) 0.8 U/kg
Study: 17045796
Drug: Continuous tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous tamoxifen (40 mg daily)
Study: 17045796
Drug: Intermittent/alternated tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent/alternated tamoxifen and medroxyprogesterone acetate (MPA, 300 mg daily)
Study: 9324165
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA; 4.0 micromol/kg x h)
Study: 9324165
Drug: L‐arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐arginine (1 mmol/kg x h)
Study: 8453706
Drug: Ifosfamide (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (3,750 mg/m2 on days 1 and 2 every 3 weeks) + Doxorubicin (30 mg/m2 for 2 days)
Study: 8453706
Drug: Doxorubicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (80 mg/m2 every 3 weeks)
Study: 8453706
Drug: Doxorubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (40 mg/m2) + Mitomycin (8 mg/m2) + Cisplatin (60 mg/m2, all given intravenously on day 1)
Study: 31899723
Drug: Suprainguinal FICB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprainguinal FICB with 30 mL of 0.375% ropivacaine
Study: 31899723
Drug: Infrainguinal FICB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrainguinal FICB with 30 mL of 0.375% ropivacaine
Study: 25529756
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg day-1 ranitidine
Study: 25529756
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg day-1 ranitidine
Study: 8544269
Drug: GG167 (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GG167 (3.6 to 16 mg, administered intranasally two or six times daily)
Study: 8544269
Drug: GG167 (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: GG167 (early treatment)
Study: 8544269
Drug: GG167 (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: GG167 (twice daily dosing)
Study: 1704089
Drug: Subcutaneous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous hydromorphone infusion
Study: 1704089
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone infusion
Study: 788739
Drug: Phenylbutazone 300
Normalized name: phenylbutazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 300 mg/day
Study: 6884415
Drug: Phenylbutazone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (various doses: 90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg, 450 mg/day)
Study: 25448497
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of atorvastatin calcium and methylprednisolone
Study: 21733697
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of fibrin spray administered topically during surgery
Study: 21733697
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving neither treatment
Study: 19268281
Drug: Acceptance-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based treatment for tinnitus distress
Study: 9513583
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg twice daily for 8 weeks)
Study: 7844297
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent carbamide peroxide bleaching gel (short application time)
Study: 7844297
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent carbamide peroxide bleaching gel (extended application time)
Study: 3132124
Drug: Heparin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (in patients with bleeding tendencies)
Study: 31379269
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (15 g of prebiotics, 5 g of probiotics containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA-6, Bifidobacterium lactis BIA-7, and Bifidobacterium longum BIA-8 (2.7×107 CFU/g each))
Study: 31379269
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (5 g probiotics with 15 g of maltodextrin as placebo)
Study: 30617950
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g of maltodextrin)
Study: 29231426
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (group B)
Study: 25467221
Drug: Nabilone (NAB)
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabilone (NAB) 0.5 mg to 3.0 mg
Study: 23246307
Drug: DTaP-IPV-Hep B-PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim)
Study: 21586234
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg daily for 52 weeks
Study: 21586234
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg daily for 52 weeks
Study: 16549733
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (3 doses of 1200 mg intravenous amoxicillin-clavulanate at induction and 6 and 12 hours postoperatively)
Study: 16549733
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (7-day course of 375 mg amoxicillin-clavulanate 3 times a day)
Study: 8781792
Drug: Endoscopic heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic heat probe therapy (median 165 J) at 24 hours
Study: 1627435
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with oral LMF (fluorouracil, 500 mg, methotrexate, 25 mg, and chlorambucil, 10 mg, on day 1; fluorouracil, 500 mg, and chlorambucil, 10 mg, on day 2)
Study: 1627435
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with oral LMF
Study: 6547563
Drug: Oestrogen/gestagen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen/gestagen treatment
Study: 3532401
Drug: Chrysanol (calcium‐aurothiopropanol‐sulfonate)
Normalized name: dimethylmethoxy chromanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysanol (calcium‐aurothiopropanol‐sulfonate) plus nonsteroid antiinflammatory drugs (NAD)
Study: 29369123
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer (intervention group)
Study: 27950666
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with TPF followed by concomitant CT/RT (Arm B)
Study: 14974922
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (33 microg/kg/day)
Study: 14974922
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (66 microg/kg/day)
Study: 10826408
Drug: Diet 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2: L‐arginine enriched by natural foods
Study: 10826408
Drug: Diet 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 3: identical to Diet 1 plus oral L‐arginine supplement
Study: 8649712
Drug: Once-daily gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily gentamicin dosing (5 mg/kg)
Study: 8649712
Drug: 8-hour gentamicin
Normalized name: gentamicin 0.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-hour gentamicin dosing (1.75 mg/kg every 8 hours)
Study: 1341599
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex 0 mg (placebo)
Study: 1341599
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex 2 mg
Study: 1341599
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex 4 mg
Study: 29952863
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) delivered at 120% motor threshold, 10 Hz, 5-second train duration, and 10-second intertrain interval for 30 minutes weekly for 5 weeks (30,000 stimuli)
Study: 27615005
Drug: Morning group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning group (MG, 9:00‐11:00 AM)
Study: 18407386
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MenC conjugate vaccine
Study: 18407386
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of MenC conjugate vaccine
Study: 12365325
Drug: Immunocorrecting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocorrecting treatment with leukinferone
Study: 12365325
Drug: Etiotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiotropic therapy
Study: 2644749
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of glucose-free 2% lignocaine
Study: 2644749
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of glucose-free 2% lignocaine
Study: 2644749
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of glucose-free 2% lignocaine
Study: 2644749
Drug: 3-4 ml
Normalized name: proline 3.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 ml of glucose-free 2% lignocaine
Study: 2644749
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of glucose-free 2% lignocaine
Study: 766574
Drug: practolol, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: practolol, 15 mg
Study: 31695330
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation under fasting conditions
Study: 31695330
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation under fasting conditions
Study: 31695330
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation under fed conditions
Study: 31695330
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation under fed conditions
Study: 31695330
Drug: Food intake
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food intake before administration
Study: 29998506
Drug: Post-HTx sST2
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-HTx sST2 levels ≥35 ng/mL (Group 2)
Study: 29998506
Drug: Post-HTx sST2
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-HTx sST2 levels <35 ng/mL (Group 1)
Study: 22079927
Drug: 10-mg hydrocortisone
Normalized name: hydrocortisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg hydrocortisone
Study: 16633143
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg/d)
Study: 17513631
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 microg/mL)
Study: 11579243
Drug: Substituted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substituted protease inhibitor(s) with abacavir, nevirapine, adefovir and hydroxyurea (n = 49)
Study: 11579243
Drug: Continued all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued all therapy (n = 32)
Study: 9360756
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg OD)
Study: 3319648
Drug: Glipizide treatment
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide treatment for 8 weeks
Study: 25330096
Drug: Agomelatine (single-dose)
DrugBank: Agomelatine (DB06594)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agomelatine (single-dose)
Study: 8071837
Drug: Placebo (single-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single-dose)
Study: 20813349
Drug: Fluoride Gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride Gel followed by no rinsing for 30 minutes
Study: 20813349
Drug: Fluoride Gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride Gel followed by rinsing with water
Study: 10965647
Drug: 6-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week treatment condition (applied relaxation and problem solving via the Internet and E-mail)
Study: 29018885
Drug: Fasting Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting Insulin
Study: 25168918
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of influenza vaccination administered 5 weeks after standard vaccination
Study: 25168918
Drug: Standard single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard single dose of influenza vaccination
Study: 22402056
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg daily
Study: 22402056
Drug: Warfarin (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted dose, INR 2.0-3.0)
Study: 20639824
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 0.1% eye drop - 1 drop 4 times daily for 30 days after cataract surgery
Study: 20639824
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% eye drop - 1 drop 2 hourly for 1 week, then 1 drop 4 hourly for 2 weeks, then 1 drop 6 hourly for 30 days after cataract surgery
Study: 9506325
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (in SAVE placebo group)
Study: 9506325
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (in SAVE captopril group)
Study: 7918923
Drug: Pentasa 2
Normalized name: Pentasa 250mg Extended-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 2 g/day
Study: 15118975
Drug: Pentasa 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 4 g/day
Study: 7918923
Drug: Pentasa 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 6 g/day
Study: 7918923
Drug: Olsalazine 2
Normalized name: olsalazine 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 2 g/day
Study: 7918923
Drug: Pentasa 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 4 g/day and 6 g/day
Study: 28875327
Drug: 200-μg selenium
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-μg selenium per day for 8 weeks
Study: 28390695
Drug: Oral ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ramipril 10 mg/day (n=8407)
Study: 28390695
Drug: Oral telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telmisartan 80 mg/day (n=8386)